The invention relates to novel antigen derivatives comprising an antigen and at least one muramylpeptide covalently bonded thereto, if appropriate via a spacer, to pharmaceutical preparations which contain such compounds and to their use as a vaccine. The novel antigen derivatives produce a pronounced increase in the immuno-response to the antigen, and in particular also a cell-medicated immunity under clinically acceptable conditions of administration.
这项发明涉及包括抗原和至少一个辅酶肽共价结合在一起的新型抗原衍
生物,如适当的话通过间隔物结合,以及包含这种化合物的药物制剂以及它们作为疫苗的用途。这种新型抗原衍
生物能够在临床可接受的给药条件下显著增加对抗原的免疫反应,特别是在细胞介导免疫方面。